A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors
- 1 December 2009
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 22 (12), 1519-1531
- https://doi.org/10.1038/modpathol.2009.122
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological LeiomyosarcomaThe American Journal of Pathology, 2009
- Differential Immunoreactivity of p16 in Leiomyosarcomas and Leiomyoma VariantsInternational Journal of Gynecological Pathology, 2008
- Clinicopathologic Factors and Nuclear Morphometry as Independent Prognosticators in KIT-positive Gastrointestinal Stromal TumorsJournal of Histochemistry & Cytochemistry, 2007
- Upregulation of Wilms’ tumour gene 1 (WT1) in uterine sarcomasEuropean Journal Of Cancer, 2007
- Differential Diagnosis of Smooth Muscle Tumors Utilizing p53, pTEN and Ki-67 Expression with Estrogen and Progesterone ReceptorsGynecologic and Obstetric Investigation, 2005
- Ki‐67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS)Acta Obstetricia et Gynecologica Scandinavica, 2004
- Estrogen receptor α and β expression in uterine leiomyomas from premenopausal womenFertility and Sterility, 2004
- Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcomaCancer, 2004
- Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcomaGynecologic Oncology, 2004
- p53 Alterations in Uterine Leiomyosarcomas versus LeiomyomasGynecologic Oncology, 1994